Overcoming Cancer Therapy Obstacles With Epitope Editing
Editing epitopes expressed on the surfaces of transplanted hematopoietic stem cells renders them resistant to AML treatments without affecting their critical functions.
Overcoming Cancer Therapy Obstacles With Epitope Editing
Overcoming Cancer Therapy Obstacles With Epitope Editing
Editing epitopes expressed on the surfaces of transplanted hematopoietic stem cells renders them resistant to AML treatments without affecting their critical functions.
Editing epitopes expressed on the surfaces of transplanted hematopoietic stem cells renders them resistant to AML treatments without affecting their critical functions.
David Liu shares how integrating chemistry and evolution in his research has directed his work on base editing techniques aimed at developing new therapeutics.
Ida Emilie Steinmark, PhD | Apr 26, 2023 | 3 min read
In a bid to address safety concerns about immune reactions during treatment with CRISPR-based therapeutics, a new technique speeds up how quickly the body destroys the DNA-cutting enzyme Cas9.
The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.
A new study indicates that the modified CRISPR-Cas9 technology will need to be further refined before it can safely be used for research and therapeutic applications.
Combining a modified Cas9 enzyme with an unrelated one derived from the immune system of the sea lamprey, researchers demonstrate yet another way to edit a single DNA nucleotide.